Press ReleaseCOUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces $30M Financing Led by Alpha Wave Ventures Press Release / lsc-webmaster
Press ReleaseCOUR NanoParticle (CNP) Technology Induces Antigen Specific Tolerance, Halting the Progression of Type 1 Diabetes in Spontaneous NOD Model Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Appoints Brian C. Bock as Chief Financial Officer Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis Press Release / lsc-webmaster
Press ReleaseIronwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S. Press Release / lsc-webmaster
Press ReleaseCOUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy Press Release / lsc-webmaster
Press ReleaseU.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC) Press Release / lsc-webmaster
